1-8 of 8
Tonglu Qiu
Close
Sort by
Journal Articles

A Single Center Real World Study of Outcome and Resistance of Bruton Tyrosine Kinase Inhibitors (BTKi) in Chinese Patients with Chronic Lymphocytic Leukeima/Small Lymphocytic Lymphoma

Huayuan Zhu, Luomengjia Dai, Yeqin Sha, Xiao Lu, Siqi Qian, Tonglu Qiu, Yi Miao, Yi Xia, Shuchao Qin, Ziyuan Zhou, Wei Wu, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4653.
https://doi.org/10.1182/blood-2023-189681
Published: 2023
Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Yi Xia, Shuchao Qin, Wei Wu, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Wei Xu, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4642.
https://doi.org/10.1182/blood-2023-188925
Published: 2023
Journal Articles

A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Huayuan Zhu, Yi Xia, Yi Miao, Shuchao Qin, Wei Wu, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 6554.
https://doi.org/10.1182/blood-2023-189110
Published: 2023
Journal Articles

Significance of the Rhoa G17V Mutation Detected By Ddpcr in Diagnostic and Monitor of Angioimmunoblastic T-Cell Lymphoma

Yi Miao, Siqi Qian, Xiao Lu, Tonglu Qiu, Shuchao Qin, Yi Xia, Lei Fan, Jianyong Li, Huayuan Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6083.
https://doi.org/10.1182/blood-2023-182617
Published: 2023
Journal Articles

Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Rui Jiang, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Hui Jin, Jianyong Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 6985–6987.
https://doi.org/10.1182/blood-2022-169720
Published: 2022
Journal Articles

Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 4117–4118.
https://doi.org/10.1182/blood-2022-170985
Published: 2022
Journal Articles

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia

Huayuan Zhu, Yeqin Sha, Yi Miao, Shuchao Qin, Hui Shen, Jingyan Qiu, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Jianyong Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 4164–4165.
https://doi.org/10.1182/blood-2022-170815
Published: 2022
Journal Articles

Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL

Yeqin Sha, Shuchao Qin, Yi Miao, Rui Jiang, Wei Wu, Yi Xia, Tonglu Qiu, Li Wang, Lei Fan, Wei Xu, Hui Jin, Jianyong Li, Huayuan Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6992–6993.
https://doi.org/10.1182/blood-2022-169907
Published: 2022